Gene:
RRAS
related RAS viral (r-ras) oncogene homolog

PharmGKB contains no prescribing info for this . Contact us to report known genotype-based dosing guidelines, or if you are interested in developing guidelines.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

Overview

Alternate Names:  Oncogene RRAS
Alternate Symbols:  None
PharmGKB Accession Id: PA34861

Details

Cytogenetic Location: chr19 : q13.33 - q13.33
GP mRNA Boundary: chr19 : 50138552 - 50143400
GP Gene Boundary: chr19 : 50135552 - 50153400
Strand: minus

Visualization

UCSC has a Genome Browser that you can use to view PharmGKB annotations for this gene in context with many other sources of information.

View on UCSC Browser
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Bisphosphonate Pathway, Pharmacodynamics
    Representation of genes involved in bisphosphonates' effects in osteoclasts.
  1. EGFR Inhibitor Pathway, Pharmacodynamics
    Model non-tissue specific cancer cell displaying genes that may be involved in the treatment using epidermal growth factor receptor specific tyrosine kinase inhibitors or monoclonal antibodies.

Curated Information ?

Evidence Gene
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
ARAF
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
BRAF
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
EGFR
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
MAP3K1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
RAF1
No related diseases are available

LinkOuts

NCBI Gene:
6237
OMIM:
165090
UCSC Genome Browser:
NM_006270
RefSeq RNA:
NM_006270
RefSeq Protein:
NP_006261
RefSeq DNA:
NT_011109
UniProtKB:
RRAS_HUMAN (P10301)
Ensembl:
ENSG00000126458
GenAtlas:
RRAS
GeneCard:
RRAS
MutDB:
RRAS
ALFRED:
LO332630R
HuGE:
RRAS
Comparative Toxicogenomics Database:
6237
ModBase:
P10301
HumanCyc Gene:
HS05020
HGNC:
10447

Common Searches